^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 765049

    i
    Other names: BI 765049, B7-H6/CD3 T-cell engager, OBT624, BI765049, OBT 624, BI-765049, OBT-624
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, Oxford BioTherap
    Drug class:
    CD3 agonist, B7-H6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    22d
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=248 --> 67
    Enrollment closed • Enrollment change • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    4ms
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (clinicaltrials.gov)
    P1, N=248, Recruiting, Boehringer Ingelheim | N=120 --> 248
    Enrollment change • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    8ms
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial completion date: May 2025 --> Dec 2028 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    9ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    12ms
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2023 --> May 2025
    Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    12ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    12ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Boehringer Ingelheim | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Combination therapy • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    1year
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Boehringer Ingelheim
    New P1 trial • Combination therapy • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    over1year
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2024 --> May 2025
    Trial completion date • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    over1year
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial primary completion date: Feb 2023 --> Nov 2023
    Trial primary completion date • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049